This week's paper from our editors-in-chief presented the idea of tying a prescription drug's cost-sharing to its clinical value to the patient.
Welcome to Paper of the Week, which looks back at research and commentary from the past 25 years in The American Journal of Managed Care®, and why they matter today. This week, we revisit one of the most important papers to appear in the journal—from our own editors in chief—A. Mark Fendrick, MD, and Michael Chernew, PhD, who in 2001 presented the idea of tying a prescription drug’s cost-sharing to its clinical value to the patient.
This concept, presented in the paper, “A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost,” is a foundation of value-based insurance design (V-BID), which both Fendrick and Chernew have examined for the past 20 years. Fendrick serves as director of The University of Michigan’s V-BID Center, while Chernew is director of Harvard’s Healthcare Markets and Regulation Lab.
For the 2001 paper, visit ajmc.com.
This week, Fendrick made a presentation to members of the Northeast Business Group on Health on V-BID’s potential for employers. He was joined by Suzanne Delbanco of Catalyst for Payment Reform. For coverage of the session, visit ajmc.com.
Reducing Low-Value Care Is Hard, but What About Just Not Paying for It?
March 14th 2024After years of efforts to reduce low-value care, panelists at the 2024 Value-Based Insurance Design Summit proposed a new strategy: drawing a line in the sand that payers will not be on the hook for these services.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Lowering Cardiometabolic Drug Costs May Improve Diabetes Health Outcomes
February 9th 2024Patients enrolled in a preventive drug list (PDL) benefit saw an 8.4% reduction in acute, preventable diabetes complication days, and PDL members residing in lower-income areas saw a 10.2% decrease compared with control members.
Read More
Key Issues Influencing 2022 Employer Health Care Strategy and Plan Design
August 31st 2021On this episode of Managed Care Cast, we speak with Ellen Kelsay, president and CEO of the Business Group on Health, on the findings from her organization's 2022 Large Employers’ Health Care Strategy and Plan Design Survey.
Listen